Researchers retrospectively reviewed the records of a series of patients who underwent onabotulinumtoxinA (Botox) injections for overactive bladder from 2007 to 2017.
Nocturnal polyuria can't be diagnosed using a standard history alone, researchers say.
A comparison of autologous fascial pubovaginal and synthetic midurethral slings and a study examining onabotulinumA (Botox) injections in the elderly population were among other female urology take-homes from AUA 2018.
“There is apparent promise here. There appears to be stability of results in those patients followed up,” says researcher Roger Dmochowski, MD.
It appears that many patients who have a good response to initial injections and subjective improvement fail to return for subsequent injections.
OnabotulinumtoxinA (Botox) appears to increase the activity of brain regions involved in sensation and processing of urinary urgency in female patients with neurogenic overactive bladder, says Rose Khavari, MD.
Among 321 scheduled telemedicine visits for patients with neurogenic bladder, the compliance rate was 91%.
Analyses with patients stratified into three groups by age showed that an emulsified microdose desmopressin acetate nasal spray (Noctiva) consistently extended the first uninterrupted sleep period in a clinically meaningful manner for patients of all ages.